Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
DNIB0600A (lifastuzumab vedotin) is an antibody-drug conjugate targeting SLC34A2 and is conjugated to monomethyl auristatin E, which leads to disruption of the microtubule network in SLC34A2-expressing cancer cells, thereby potentially inhibiting cell proliferation (PMID: 29401246).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DNIB0600A||Lifastuzumab vedotin|RG-7599||DNIB0600A (Lifastuzumab vedotin) is an antibody-drug conjugate consists of an antibody targeting SLC34A2 and monomethyl auristatin E, which may lead to disruption of the microtubule network in SLC34A2-expressing cancer cells, thereby potentially inhibiting cell proliferation (PMID: 29401246, PMID: 32534811, PMID: 31540980).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01991210||Phase II||DNIB0600A Pegylated liposomal-doxorubicin||A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer||Terminated||USA | FRA | ESP | CAN | BEL||2|